Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Heather Jane Au"'
Autor:
Nadine M Magoski, Dongsheng Tu, Christopher J. O'Callaghan, David Wyld, Michael Brundage, Michael Jefford, G. Knight, Christos S. Karapetis, Nick Pavlakis, Hagen F. Kennecke, Derek J. Jonker, Jeremy Shapiro, Danielle Charpentier, Malcolm J. Moore, Sheryl Koski, Heather-Jane Au, John Zalcberg
Publikováno v:
Flinders University PURE
Purpose National Cancer Institute of Canada Clinical Trials Group CO.17 demonstrated the antiepidermal growth factor receptor (anti-EGFR) monoclonal antibody cetuximab improves overall and progression-free survival in patients with advanced, chemothe
Autor:
Konrad Fassbender, Stephen Chia, Philip Jacobs, Heather-Jane Au, Tallal Younis, Shailendra Verma, Kamran Golmohammadi
Publikováno v:
Breast Cancer Research and Treatment. 114:579-587
Purpose BCIRG 001 demonstrated prolonged disease-free (DFS) and overall survival (OS) but increased toxicity for adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) versus 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) in women with node
Autor:
Anil A. Joy, Karen King, Sambasivarao Damaraju, Robert R. Bies, Michael Smylie, Carla M. Prado, Larissa J. Vos, Michael B. Sawyer, Vijaya L. Damaraju, Sheryl Koski, Andrew Scarfe, Mark Clemons, Katia Tonkin, Edith Pituskin, John R. Mackey, Diana Carandang, Carol E. Cass, Heather-Jane Au, John Hanson, Michelle Kuzma
Publikováno v:
Clinical breast cancer. 16(2)
Background Epirubicin is metabolized by uridine glucuronosyltransferase 2B7 (UGT2B7), an enzyme rich in single nucleotide polymorphisms (SNPs). We studied whether the −161 C > T germline SNP in UGT2B7 was related to epirubicin metabolism and whethe
Autor:
Jay Easaw, Derek J. Jonker, Ian Walters, Jenny Shannon, Jeremy Shapiro, Siobhan Ng, Lillian L. Siu, John Zalcberg, Christopher J. O'Callaghan, Andrew Strickland, Thierry Alcindor, Rami Kotb, Malcolm J. Moore, Heather Jane Au, Fabyolla El-Tahche, Sabe Sabesan, Mark Jeffery, Muhammad Salim, Jolie Ringash, Dongsheng Tu
Publikováno v:
Cancer. 120(2)
BACKGROUND The CO.20 trial randomized patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer to receive cetuximab (CET) plus brivanib alaninate (BRIV) or CET plus placebo (CET/placebo). METHODS Quality of life (QoL) was
Autor:
John A. Glaspy, Dennis J. Slamon, Wolfgang Eiermann, Maria J. Santana, Valerie Bee, John Crown, Tadeusz Pienkowski, Miguel Martin, S. Sehdev, Deepa Lalla, John R. Mackey, Tommy Fornander, Nicholas J. Robert, Dave P. Miller, Jean Marc Ferrero, Tamás Pintér, Mei Ching Liu, Arlene Chan, Heather Jane Au, M. Pawlicki
Publikováno v:
The oncologist. 18(7)
Background. This study aims to describe and compare health-related quality of life (HRQL) in patients with node-positive and high-risk node-negative HER2-positive early breast cancer receiving adjuvant docetaxel and trastuzumab-based or docetaxel-bas
Autor:
Samuel Y Ngan, Christopher J. O'Callaghan, Iain G. Ward, Jennifer Harvey, Heather-Jane Au, Andrew Kneebone, Sonya Stephens, Rebecca Wong, James Joseph Biagi, Keyue Ding, Tirath Nijjar, Rajarshi Roy, Michael Penniment, Thomas Sullivan
Publikováno v:
Journal of Clinical Oncology. 32:163-163
163 Background: The dominant symptom for pts with esophageal cancer is dysphagia. Palliative radiotherapy is commonly employed for symptom relief. We report the effect on QoL in our study comparing a 2-3 week course of RT alone vs the same RT with a
Autor:
Michael Penniment, Thomas Sullivan, Samuel Y Ngan, Andrew Kneebone, C.J. O’Callaghan, Tirath Nijjar, Rajarshi Roy, Heather-Jane Au, Jennifer Harvey, Liam Mulroy, James Joseph Biagi, Raimond Wong, Sonya Stephens, Iain G. Ward
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 90:S3
Best Practice in Advanced Esophageal Cancer: A Report on TransTasman Radiation Oncology Group TROG 03.01 and NCIC CTG ES.2 Multinational Phase 3 Study in Advanced Esophageal Cancer (OC) ComparingQualityofLife(QOL)andPalliationofDysphagia inPatients T
Autor:
Dianne M. Bodnar, Denis Soulières, John R. Mackey, Stephanie Smith, Heather-Jane Au, Anil A. Joy, Sheryl Koski, Andrew Scarfe, Michael Smylie, Katia Tonkin
Publikováno v:
Clinical breast cancer. 5(4)
The addition of capecitabine to docetaxel on a 3-week schedule resulted in superior response rate, increased time to progression (TTP), and improved overall survival in patients with anthracycline-pretreated metastatic breast cancer (MBC). Because th
Autor:
Kelvin K. W. Chan, Jeffrey S Hoch, Christos S. Karapetis, Jeremy Shapiro, Heather-Jane Au, Nick Pavlakis, Derek J. Jonker, Christopher J. O'Callaghan, Nicole Mittmann, Timothy J. Price, Michael Brundage, Guy van Hazel, Natasha B. Leighl, Niall C. Tebbutt, Dongsheng Tu, Jolie Ringash, John Zalcberg
Publikováno v:
Journal of Clinical Oncology. 32:547-547
547 Background: The National Cancer Institute of Canada CO17 study, which showed that patients with advanced colorectal cancer had improved overall survival and derived health related quality of life benefits (measured with EORTC QLQ C30) when treate
Autor:
Malcolm J. Moore, Paul Wheatley-Price, Wendy R. Parulekar, Christopher J. O'Callaghan, Chee Lee, Michael M. Vickers, Michael Brundage, Heather-Jane Au, Dongsheng Tu, Derek J. Jonker, Jolie Ringash, David Goldstein
Publikováno v:
Journal of Clinical Oncology. 31:4053-4053
4053 Background: There is insufficient information regarding the prognostic significance of baseline Quality of life (QoL) scores on overall survival (OS) and adverse events (AEs) in advanced pancreatic cancer. Methods: QoL was assessed prospectively